| AstraZeneca56 programs in shared conditions | 24 · 10 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms +21 | capivasertib, datopotamab deruxtecan, camizestrant +6 | - AstraZeneca’s trastuzumab deruxtecan vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT05048797)
- AstraZeneca’s rilvegostomig vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT06868277)
- Merck & Co., Inc’s nemtabrutinib vs acalabrutinib (US & EU rights: AstraZeneca) (Leukemia, Lymphocytic, Chronic, B-Cell, NCT06136559)
- and 9 more
|
| Bristol-Myers Squibb26 programs in shared conditions | 16 · 8 with both in phase 3Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lymphoma, Follicular +13 | xanomeline, trospium, trospium chloride +7 | - Bristol-Myers Squibb’s pumitamig vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07361510)
- Merck & Co., Inc’s patritumab deruxtecan in a combination vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Breast Neoplasms, NCT07060807)
- Merck & Co., Inc’s sacituzumab tirumotecan in a combination vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Breast Neoplasms, NCT06312176)
- and 9 more
|
| Gilead Sciences8 programs in shared conditions | 4 · 3 with both in phase 3HIV Infections, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms +1 | lenacapavir, teropavimab, zinlirvimab +4 | - Merck & Co., Inc’s alimatravir vs Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (EU rights: Gilead Sciences) (Acquired Immunodeficiency Syndrome, NCT07071623)
- Merck & Co., Inc’s islatravir in a combination vs Emtricitabine (EU rights: Gilead Sciences) (Acquired Immunodeficiency Syndrome, NCT07266831)
- Merck & Co., Inc’s islatravir in a combination vs Emtricitabine (EU rights: Gilead Sciences) (Acquired Immunodeficiency Syndrome, NCT06891066)
- and 7 more
|
| CSPC Pharmaceutical Group Limited28 programs in shared conditions | 17 · 5 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Hyperlipoproteinemia Type II +14 | Docetaxel, anbenitamab, anbenitamab repodatecan +6 | - CSPC Pharmaceutical Group Limited’s Anti-EGFR Antibody-drug Conjugate CPO301 in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07672223)
- CSPC Pharmaceutical Group Limited’s enlonstobart in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07672223)
- CSPC Pharmaceutical Group Limited’s anbenitamab in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Stomach Neoplasms, NCT07332533)
- and 4 more
|
| Jiangsu HengRui Medicine Co., Ltd.56 programs in shared conditions | 25 · 10 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Hypercholesterolemia +22 | HRS-6209, HRS-8080, trastuzumab rezetecan +8 | - Jiangsu HengRui Medicine Co., Ltd.’s ruzaltatug rezetecan in a combination vs sacituzumab tirumotecan (most trials: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07895992)
- Merck & Co., Inc’s opevesostat in a combination vs prednisone acetate (most trials: Jiangsu HengRui Medicine Co., Ltd.) (Prostatic Neoplasms, NCT06136650)
- Jiangsu HengRui Medicine Co., Ltd.’s trastuzumab rezetecan in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Triple Negative Breast Neoplasms, NCT07679360)
- and 1 more
|